Japan approves Gilead Sciences' remdesivir as Covid-19 drug | The Business Standard
Skip to main content
  • Home
  • Economy
    • Aviation
    • Bazaar
    • Budget
    • Industry
    • NBR
    • RMG
    • Corporates
  • Stocks
  • Analysis
  • World+Biz
  • Sports
  • Features
    • Book Review
    • Brands
    • Earth
    • Explorer
    • Fact Check
    • Family
    • Food
    • Game Reviews
    • Good Practices
    • Habitat
    • Humour
    • In Focus
    • Luxury
    • Mode
    • Panorama
    • Pursuit
    • Wealth
    • Wellbeing
    • Wheels
  • Epaper
    • GOVT. Ad
  • More
    • Subscribe
    • Videos
    • Thoughts
    • Splash
    • Bangladesh
    • Supplement
    • Infograph
    • Archive
    • COVID-19
    • Games
    • Long Read
    • Interviews
    • Offbeat
    • Podcast
    • Quiz
    • Tech
    • Trial By Trivia
    • Magazine
  • বাংলা
The Business Standard

Monday
June 05, 2023

Sign In
Subscribe
  • Home
  • Economy
    • Aviation
    • Bazaar
    • Budget
    • Industry
    • NBR
    • RMG
    • Corporates
  • Stocks
  • Analysis
  • World+Biz
  • Sports
  • Features
    • Book Review
    • Brands
    • Earth
    • Explorer
    • Fact Check
    • Family
    • Food
    • Game Reviews
    • Good Practices
    • Habitat
    • Humour
    • In Focus
    • Luxury
    • Mode
    • Panorama
    • Pursuit
    • Wealth
    • Wellbeing
    • Wheels
  • Epaper
    • GOVT. Ad
  • More
    • Subscribe
    • Videos
    • Thoughts
    • Splash
    • Bangladesh
    • Supplement
    • Infograph
    • Archive
    • COVID-19
    • Games
    • Long Read
    • Interviews
    • Offbeat
    • Podcast
    • Quiz
    • Tech
    • Trial By Trivia
    • Magazine
  • বাংলা
MONDAY, JUNE 05, 2023
Japan approves Gilead Sciences' remdesivir as Covid-19 drug

Coronavirus chronicle

Reuters
07 May, 2020, 07:05 pm
Last modified: 07 May, 2020, 07:06 pm

Related News

  • US seeking explosives in Japan for Ukraine artillery shells
  • Japan slammed by torrential rain as typhoon nears
  • Japan experienced warmest spring on record
  • Japan allows nuclear plants to operate beyond 60 years
  • Japan puts missile defences on alert as North Korea warns of satellite launch

Japan approves Gilead Sciences' remdesivir as Covid-19 drug

Remdesivir was granted authorisation last week by the US Food and Drug Administration for emergency use for the disease caused by the coronavirus

Reuters
07 May, 2020, 07:05 pm
Last modified: 07 May, 2020, 07:06 pm
FILE PHOTO: A lab technician visually inspects a filled vial of investigational coronavirus disease (COVID-19) treatment drug remdesivir at a Gilead Sciences facility in La Verne, California, U.S. March 11, 2020. Picture taken March 11, 2020. Gilead Sciences Inc/Handout via REUTERS.
FILE PHOTO: A lab technician visually inspects a filled vial of investigational coronavirus disease (COVID-19) treatment drug remdesivir at a Gilead Sciences facility in La Verne, California, U.S. March 11, 2020. Picture taken March 11, 2020. Gilead Sciences Inc/Handout via REUTERS.

Japan has approved Gilead Sciences Inc's remdesivir as a treatment for Covid-19, the health ministry said on Thursday, making it the country's first officially authorized drug for the coronavirus disease.

Japan reached the decision just three days after the US drugmaker filed for fast-track approval for the treatment.

Remdesivir will be give to patients with severe Covid-19 symptoms, a Japanese health ministry official said at a press briefing. With no other approved treatments for Covid-19, interest in the drug is growing around the world.

Remdesivir was granted authorisation last week by the US Food and Drug Administration for emergency use for the disease caused by the coronavirus.

Japan, with just over 16,000 infections and under 800 deaths, has recorded has fewer cases than other major industrialized nations.

However, a steady rise in cases has put pressure on medical facilities in some parts of the country, and drug that helps patients recover more quickly could help in freeing up hospital beds.

On Monday, Japanese Prime Minister Shinzo Abe extended a month-long state of emergency until the end of May in a bid to slow the spread of the coronavirus.

Gilead on Tuesday said it was in discussion with several companies, including generic drugmakers in India and Pakistan to produce remdesivir in large quantities.

Top News

Japan / remdesivir

Comments

While most comments will be posted if they are on-topic and not abusive, moderation decisions are subjective. Published comments are readers’ own views and The Business Standard does not endorse any of the readers’ comments.

Top Stories

  • An anatomy of power crisis
    An anatomy of power crisis
  • How BSRM turns steel waste into eco-friendly construction material
    How BSRM turns steel waste into eco-friendly construction material
  • Dhaka-Tongi-Joydebpur railway expansion project cost to rise 294%
    Dhaka-Tongi-Joydebpur railway expansion project cost to rise 294%

MOST VIEWED

  • Covid is no longer global health emergency: WHO
    Covid is no longer global health emergency: WHO
  • Federal police officers stand guard near the house of former Brazilian President Jair Bolsonaro, during a search operation at his home, in Brasilia, Brazil, 3 May, 2023. REUTERS/Adriano Machado
    Bolsonaro home raided, phone seized in Brazil vaccine records probe
  • World Health Organization logo is reflected in a drop on a syringe needle in this illustration photo taken March 16, 2021. REUTERS/Dado Ruvic/Illustration//File Photo
    Covid here to stay but moving out of emergency phase: WHO
  • India's active case count now stands at 3.90 per cent. ( HT file Photo)
    India reports 12,591 new Covid cases today, 20% more than yesterday
  • People queue up outside a quick test centre to take their coronavirus disease (Covid-19) antigen rapid tests, in Singapore September 21, 2021. Photo :Reuters
    Singapore witnesses new Covid wave: ‘Cases are mostly mild’
  • India's active case count now stands at 3.90 per cent. ( HT file Photo)
    India logs 5,676 new Covid cases, active infections cross 37,000-mark

Related News

  • US seeking explosives in Japan for Ukraine artillery shells
  • Japan slammed by torrential rain as typhoon nears
  • Japan experienced warmest spring on record
  • Japan allows nuclear plants to operate beyond 60 years
  • Japan puts missile defences on alert as North Korea warns of satellite launch

Features

Beating plastic pollution: Local startups build businesses around waste

Beating plastic pollution: Local startups build businesses around waste

2h | Panorama
New battleground of global powers

New battleground of global powers

17h | Panorama
Understanding the Indo-Pacific: A case of two rivalries

Understanding the Indo-Pacific: A case of two rivalries

17h | Panorama
US and its allies in the Ind-Pacific

US and its allies in the Ind-Pacific

17h | Panorama

More Videos from TBS

Young Entrepreneurs Beating Plastic Pollution

Young Entrepreneurs Beating Plastic Pollution

48m | TBS Stories
The fitness industry of Bangladesh tries to reshape from corona effect

The fitness industry of Bangladesh tries to reshape from corona effect

15h | TBS Stories
Ukraine ready to launch counteroffensive

Ukraine ready to launch counteroffensive

18h | TBS World
Mughal Emperor Shah Jahan's food on the streets of Dhaka

Mughal Emperor Shah Jahan's food on the streets of Dhaka

23h | TBS Food

Most Read

1
bKash denied permission to pay $4.10 lakh for Argentina football partnership
Banking

bKash denied permission to pay $4.10 lakh for Argentina football partnership

2
Boeing offers Biman its latest 787-10 Dreamliner
Bangladesh

Boeing offers Biman its latest 787-10 Dreamliner

3
Photo: Noor-A-Alam/TBS
Splash

The Night Dhaka did NOT vibe with Anuv Jain

4
Country's first floating solar power plant connected to national grid
Energy

Country's first floating solar power plant connected to national grid

5
File Photo: Mohammad Minhaj Uddin/TBS
Bangladesh

Low-cost housing planned for 4 lakh Bangabandhu Shilpa Nagar workers

6
Photo: TBS
Environment

Green space in Dhaka North declines 66% in 3 decades: Study

EMAIL US
[email protected]
FOLLOW US
WHATSAPP
+880 1847416158
The Business Standard
  • About Us
  • Contact us
  • Sitemap
  • Privacy Policy
  • Comment Policy
Copyright © 2023
The Business Standard All rights reserved
Technical Partner: RSI Lab

Contact Us

The Business Standard

Main Office -4/A, Eskaton Garden, Dhaka- 1000

Phone: +8801847 416158 - 59

Send Opinion articles to - [email protected]

For advertisement- [email protected]